Progressive (PGR) Rule 144 Notice: 2,218 Shares from Vesting to be Sold
Rhea-AI Filing Summary
Progressive Corporation (PGR) Form 144 notice shows a proposed sale of 2,218 common shares held at Fidelity with an aggregate market value of $556,230.04, to be sold on 08/22/2025 on the NYSE. The shares were acquired on 07/25/2025 through restricted stock vesting and were marked as compensation. The filing also discloses prior sales by the same person, John J. Murphy, of 4,000 shares on 06/20/2025 for $1,041,520.00 and 2,218 shares on 07/28/2025 for $552,814.32. The notice includes the customary insider representation that no undisclosed material adverse information is known.
Positive
- Transaction complies with Rule 144 disclosure, documenting acquisition dates, nature of acquisition, broker, sale dates, and proceeds
- Securities originated from restricted stock vesting, indicating compensation-related issuance rather than open-market purchases
Negative
- Insider sales occurred recently (4,000 shares on 06/20/2025 and 2,218 shares on 07/28/2025), which may prompt investor questions despite small size relative to outstanding shares
Insights
TL;DR Routine insider sales from vested restricted stock; transaction size appears small relative to company equity outstanding.
The filing documents a Rule 144 notice for sale of 2,218 common shares acquired by restricted stock vesting and listed for sale on the NYSE. The seller previously disposed of 4,000 and 2,218 shares in the past month. The aggregate market value reported ($556,230) is negligible versus the reported shares outstanding (586,208,487), indicating these are routine officer/employee liquidity events rather than material capital structure changes.
TL;DR Disclosure follows Rule 144 norms; includes the required insider attestation regarding undisclosed material information.
The notice states the securities were obtained via restricted stock vesting and sold through a brokerage, with dates and proceeds disclosed for recent transactions by the same individual. The form includes the standard attestation that the filer is not aware of undisclosed material adverse information, and warns about penalties for false statements. No indications of trading plan dates or 10b5-1 adoption are provided in the remarks section.